Azithromycin for Children Hospitalized With Asthma

• Status: Terminated
• Trial end date: 2018-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Asthma is a chronic lung condition in children, and often requires hospitalization for acute exacerbations. Azithromycin has been used successfully in other chronic lung diseases, including cystic fibrosis. Despite limited clinical evidence, some pediatricians use azithromycin in children hospitalized with asthma, citing either treatment of atypical pathogens or its proposed anti-inflammatory properties. This study proposes a clinical trial to determine if azithromycin will shorten length of stay in children hospitalized with acute asthma exacerbations.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• 4-12 years of age

• Admission diagnosis of asthma at the Children's Hospital at Montefiore

• History of persistent asthma (as defined by National Heart, Lung, and Blood Institute)

Exclusion Criteria:

• Concurrent bacterial infection requiring antibiotics

• Antibiotics received within previous 2 weeks

• Contraindication to azithromycin (including allergy to macrolides)

• Chronic lung disease other than asthma (including bronchopulmonary dysplasia, cystic fibrosis, bronchiectasis) or home oxygen requirement

• Immunodeficiency (primary or acquired)

• Chronic systemic steroid use

• Invasive or non-invasive mechanical ventilation required acutely as result of current asthma admission

• Significant cardiac co-morbidity (including hemodynamically significant cardiac disease or arrhythmia)

• Liver disease (hepatitis)

• Pregnancy

• Seizure disorder, currently on anti-epileptic medication)

• Receiving albuterol every 4 hours (q4h) at the time of enrollment

• Previous enrollment in study